tm logo

Monitor this mark

View On USPTO

ZURZUVAE
Live/Registered
REGISTERED

on 16 Apr 2024

Last Applicant/ Owned by

Sage Therapeutics, Inc.

215 First Street

Cambridge

MA

02142

Serial Number

97325024 filed on 22nd Mar 2022

Registration Number

7361152 registered on 16th Apr 2024

in the Principal Register

Correspondent Address

Steven A. Abreu

Steven A. Abreu SUNSTEIN LLP

BOSTON, MA 02110

United States

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

ZURZUVAE

Pharmaceutical preparations for use in the treatment of central nervous system diseases and disorders, depression, anxiety disorder, and bipolar depression

Classification Information

Class [005]
Pharmaceutical Products

Pharmaceutical preparations for use in the treatment of central nervous system diseases and disorders, depression, anxiety disorder, and bipolar depression

First Use Date in General

05th Dec 2023

First Use Date in Commerce

05th Dec 2023

Mark Details

Serial Number

No 97325024

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 4362/2037

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History

Show more

Status DateAction Taken
16th Apr 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
16th Apr 2024REGISTERED-PRINCIPAL REGISTER
09th Mar 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08th Mar 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01st Mar 2024STATEMENT OF USE PROCESSING COMPLETE
29th Feb 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
06th Feb 2024TEAS STATEMENT OF USE RECEIVED
06th Feb 2024USE AMENDMENT FILED
27th Oct 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24th Oct 2023SOU EXTENSION 1 GRANTED